169 related articles for article (PubMed ID: 4588817)
1. [Oral therapy in diabetes].
Kirkeby K
Tidsskr Nor Laegeforen; 1973 Aug; 93(23):1620-1. PubMed ID: 4588817
[No Abstract] [Full Text] [Related]
2. [Should the prescription of oral antidiabetic drugs be more limited? Results from controlled clinical trials].
Folling I
Tidsskr Nor Laegeforen; 1973 Aug; 93(23):1604-6. PubMed ID: 4769481
[No Abstract] [Full Text] [Related]
3. Audit confirms conclusions of UGDP study on oral diabetes drugs.
FDA Drug Bull; 1978 Dec-1979 Jan; 8(6):34-6. PubMed ID: 720789
[No Abstract] [Full Text] [Related]
4. Editorial: Oral hypoglycemic drugs.
Scoville AB
J Tenn Med Assoc; 1975 Apr; 68(4):319-20. PubMed ID: 1117723
[No Abstract] [Full Text] [Related]
5. [Heart death and oral antidiabetics; the last judgement].
Touber JL
Ned Tijdschr Geneeskd; 1975 Sep; 119(39):1506-8. PubMed ID: 1101083
[No Abstract] [Full Text] [Related]
6. Antidiabetic agents and vascular events.
Keen H
J Clin Pathol Suppl (R Coll Pathol); 1975; 9():99-105. PubMed ID: 783218
[No Abstract] [Full Text] [Related]
7. The oral hypoglycemic controversy. Stay as sweet as you are.
Gregory DR
Leg Aspects Med Pract; 1979 Mar; 7(3):16-9. PubMed ID: 106193
[No Abstract] [Full Text] [Related]
8. The influence of diagnostic criteria on the mortality findings in the University Group Diabetic Programme study of diabetic therapy.
Gray RH
Med J Aust; 1973 Mar; 1(12):594-6. PubMed ID: 4573383
[No Abstract] [Full Text] [Related]
9. Letter: Oral hypoglycaemics in diabetes mellitus.
Keen H; Jarrett RJ; Fuller JH
Lancet; 1975 Nov; 2(7940):865. PubMed ID: 53342
[No Abstract] [Full Text] [Related]
10. [The venture of University Group Diabetes Program (UGDP). Some personal reflexions. Tolbutamide and phenformin under accusation].
Pirart J
Nouv Presse Med; 1972 Jan; 1(5):325-8. PubMed ID: 5010448
[No Abstract] [Full Text] [Related]
11. The tolbutamide controversy.
Compr Ther; 1975 May; 1(1):19-20. PubMed ID: 1222531
[No Abstract] [Full Text] [Related]
12. Oral hypoglycaemics in diabetes mellitus.
Lancet; 1975 Sep; 2(7933):489-91. PubMed ID: 51292
[No Abstract] [Full Text] [Related]
13. The FDA and hypoglycemic drugs.
Davidson JK
JAMA; 1975 May; 232(8):853-5. PubMed ID: 1091764
[No Abstract] [Full Text] [Related]
14. Comments on the UGDP study.
Schöffling K
Horm Metab Res; 1974; Suppl 4():188-91. PubMed ID: 4608018
[No Abstract] [Full Text] [Related]
15. [University Group Diabetes Program. The UGDP investigation remains clinically unacceptable].
Aarseth S
Tidsskr Nor Laegeforen; 1976 Aug; 96(22):1148. PubMed ID: 951693
[No Abstract] [Full Text] [Related]
16. Phenformin and vascular complications of diabetes.
Med Lett Drugs Ther; 1972 Jan; 14(1):1-2. PubMed ID: 4567560
[No Abstract] [Full Text] [Related]
17. Clinical pharmacology of oral antidiabetic agents (second of two parts).
Shen SW; Bressler R
N Engl J Med; 1977 Apr; 296(14):787-93. PubMed ID: 320484
[No Abstract] [Full Text] [Related]
18. Controlled clinical trials and the tolbutamide controversy.
Lavietes PH
Conn Med; 1971 Apr; 35(4):271-2. PubMed ID: 4927818
[No Abstract] [Full Text] [Related]
19. Oral diabetic drugs again held hazardous.
J Tenn Med Assoc; 1975 Apr; 68(4):343. PubMed ID: 1117724
[No Abstract] [Full Text] [Related]
20. Oral hypoglycaemic agents.
Med J Aust; 1973 Mar; 1(12):570-1. PubMed ID: 4700542
[No Abstract] [Full Text] [Related]
[Next] [New Search]
